Everolimus (Afinitor™)

Status: Currently a NF2 Clinical Trial

Trade Name:

Afinitor™ Fermentek^TM

Synonyms:

RAD-001, RAD001, Certican, Afinitor, Zortress, Sirolimus,
SDZ-RAD, RAD001, Everolimus [USAN], RAD 001, Rapamycin,
42-O-(2-hydroxyethyl)-, UNII-9HW64Q8G6G

Pharmaceutical Company:

Novartis

Legal Status:

℞ - Trial

Administered By:

Pill - Oral

Tumor Target:

Vestibular Schwannoma

Protein Target:

mTOR Inhibitors - specifically mTORC1

Formula:

C₅₃H₈₃NO₁₄

PubChem

CID 6442177

ChemSpider

21106307

NF2 Trials

Recruiting: NCT01345136
NCT02352844
Active: NCT01490476 & NCT01880749
Completed: NCT01419639 &
NCT01024946

Side Effects

Infections, anemia, anorexia, hyperglycemia, hyperlipidemia, headache, pneumonitis, epistaxis, GI disorders.

Most common reason of inability to remain on Everolimus was irritation of mucous membranes. Mucous membranes an epithelial tissue that secretes mucus and that lines many body cavities and tubular organs including the gut and respiratory passages. - mouth or on the genitals.

Common Side Effects

• Lung and Breathing Problems
• Infections
• Kidney Failure
• Mouth and Vaginal Ulcers
• Liver problems
• Vaccinations - patients should not have live vaccinations while on Afinitor
• Contraindicated with certain medications and certain foods

Additional Possible Side Effects:

• Feeling Weak
• Cough
• Shortness of Breath
• Diarrhea
• Rash, Dry Skin, Itching
• Nausea and Vomiting
• Fever
• Loss of Appetite
• Swelling - Arms, Legs, Feet or Ankles
• Infections - Respiratory Tract, Sinuses and Ears
• Constipation
• Stomach pain
• Seizure
• Headache
• Dizziness
• Stuffy / Runny Nose
• change in personality
• Low White Cell Count
• High Fat Content in Blood

Other Uses

• Advanced Kidney Cancer
• Renal Transplantorgan Rejection Prevention
• Subependymal Giant Cell Astrocytoma (SEGA)
• Progressive / Metastatic Pancreatic Neuroendocrine Tumors
• Breast Cancer

Notes:

Everolimus or similar may be neded for management of skin irritation

Sources

• Salido-Vallejo, R., G. Garnacho-Saucedo, and A. Velez. "Elucidation of the mTOR pathway and therapeutic applications in dermatology." Actas Dermo-Sifiliograficas (English Edition) 107.5 (2016): 379-390. Source: http://www.sciencedirect.com/science/article/pii/S1578219016300154 | DOI: https://doi.org/10.1016/j.adengl.2016.03.001
• Karajannis, Matthias A., et al. "Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas." Neuro-oncology 16.2 (2014): 292-297. Source: https://academic.oup.com/neuro-oncology/article/16/2/292/1084065 | DOI: https://doi.org/10.1093/neuonc/not150